The Influence of Polymorphism NRG-1 RS35753505 C/T on Neuregulin Level 1 in Neonates Less Than a Month According to Pregnancy Period
Handling premature babies is a significant challenge in the medical world today. One of the most crucial aspects that needs to be considered is how to reduce the risk of morbidity, which can have a lasting impact on the long-term development of the baby. Neuregulin 1 (NRG-1) plays a vital role as a natural protector in fetal development. Decreased levels of NRG-1 can interfere with the formation of surfactants in the lungs of premature babies, and also affect various other organs such as the heart, brain, nerves, and immune systems. Understanding the relationship between NRG-1 polymorphism and NRG-1 levels is essential for developing effective interventions to reduce the risk of morbidity in premature babies .
The Importance of Neuregulin 1 (NRG-1) in Fetal Development Neuregulin 1 (NRG-1) is a protein that plays a crucial role in the development of the fetus. It acts as a natural protector, ensuring the proper formation of various organs and tissues. NRG-1 is involved in the regulation of cell growth, differentiation, and survival . Decreased levels of NRG-1 can lead to various complications, including respiratory distress syndrome, heart defects, and neurological disorders. Therefore, it is essential to understand the factors that influence NRG-1 levels in premature babies.
This study uses a longitudinal design involving 48 premature neonates. Neonates with severe congenital abnormalities are not included in the study. Measurement of NRG-1 levels is carried out using the ELISA method, while polymorphism analysis is carried out with PCR . Short-term morbidity is monitored for 72 hours after birth. Bivariate analysis was conducted using the Chi Square, Fisher's Exact Test, Kruskal Wallis, and Mann-Whitney U Test tests. While multivariate analysis is carried out with logistics regression, with a p-value <0.05 is considered significant at a 95% confidence interval.
The results showed that neonates with T/T genotypes have higher NRG-1 levels compared to two other genotypes. Similar findings can also be seen in the subject with a T allele which has a higher NRG-1 level than the C allele. Meanwhile, neonates with genotypes C/C and C/T have a higher risk of experiencing short-term morbidity, each of 13, each 33 times (p = 0.003) and 6.19 times (p = 0.019), compared to neonates which have T/T genotype. In addition, the existence of allele C increases the risk of short-term morbidity to 4.04 times (p = 0.001). Low NRG-1 levels are also associated with an increased risk of short-term morbidity by 7.53 times (p = 0.008) if it coincides with the NRG-1 gene polymorphism.
From this study, it can be concluded that polymorphism in the NRG-1 gene (SNP) affects NRG-1 levels and the risk of short-term morbidity in neonates. Neonates that have genotypes C/C and C/T, as well as the presence of alleles C, are at risk of decreasing NRG-1 levels and increasing short-term morbidity events. This finding is important for premature baby management, so that it can be a reference in an effort to reduce complications and facilitate the optimal growth of premature babies in the future .
By understanding the relationship between NRG-1 polymorphism and NRG-1 levels, health professionals can be better in designing interventions to reduce the risk of morbidity in premature babies. This study also provides insight into the importance of genetics in neonatal health conditions and can be a basis for further research in this field. In addition, for parents or premature baby caregivers, this knowledge can help them understand the risks that might be faced and the steps that can be taken to support the health of their babies.
This study highlights the importance of further research in the field of neonatal health and genetics. Understanding the genetic factors that influence NRG-1 levels can lead to the development of targeted interventions to reduce the risk of morbidity in premature babies . Additionally, this study provides a foundation for further research into the role of NRG-1 in fetal development and its potential as a therapeutic target for the treatment of premature babies.
This study has several limitations. The sample size is relatively small, and the study only includes premature neonates . Additionally, the study only examines the relationship between NRG-1 polymorphism and NRG-1 levels, and does not explore other potential factors that may influence NRG-1 levels. Future studies should aim to recruit a larger sample size and explore other potential factors that influence NRG-1 levels .
In conclusion, this study highlights the importance of understanding the relationship between NRG-1 polymorphism and NRG-1 levels in premature babies. The findings of this study have important implications for premature baby management and can be a reference in an effort to reduce complications and facilitate the optimal growth of premature babies in the future .Frequently Asked Questions (FAQs) About the Influence of Polymorphism NRG-1 RS35753505 C/T on Neuregulin Level 1 in Neonates Less Than a Month According to Pregnancy Period
A: Neuregulin 1 (NRG-1) is a protein that plays a crucial role in the development of the fetus. It acts as a natural protector, ensuring the proper formation of various organs and tissues. NRG-1 is involved in the regulation of cell growth, differentiation, and survival.
A: The NRG-1 RS35753505 C/T polymorphism is a genetic variation that affects the expression of NRG-1. This polymorphism has been associated with decreased levels of NRG-1, which can lead to various complications in premature babies.
A: The study's findings suggest that premature babies with the C/C or C/T genotypes, or those with the presence of allele C, are at risk of decreasing NRG-1 levels and increasing short-term morbidity events. This information can be used to develop targeted interventions to reduce the risk of morbidity in premature babies .
A: Health professionals can use the study's findings to develop targeted interventions to reduce the risk of morbidity in premature babies. This may include genetic testing to identify premature babies at risk of decreased NRG-1 levels, and the development of personalized treatment plans to address these risks .
A: The study has several limitations, including a relatively small sample size and the exclusion of premature babies with severe congenital abnormalities. Future studies should aim to recruit a larger sample size and explore other potential factors that influence NRG-1 levels .
A: The study's findings have important implications for the field of neonatal health. Understanding the genetic factors that influence NRG-1 levels can lead to the development of targeted interventions to reduce the risk of morbidity in premature babies, and may also provide insights into the role of NRG-1 in fetal development .
A: Parents or premature baby caregivers can use the study's findings to understand the risks that their babies may face, and to take steps to support their health. This may include working with healthcare professionals to develop a personalized treatment plan, and staying informed about the latest research and developments in the field of neonatal health .
A: The next steps in research on this topic will depend on the findings of future studies. However, potential areas of investigation may include the development of targeted interventions to reduce the risk of morbidity in premature babies, and the exploration of other potential factors that influence NRG-1 levels .